Marcantonio Fiorentino, MD
Infectious Disease · Canton, OHNPI 1992701130
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 390 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.
Across 390 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$1K
- Merck$840
- AbbVie$729
- Melinta Therapeutics, LLC$579
- Johnson & Johnson$492
- plus $2K from 18 others
What the payments were for
- Consulting fees$1001%
- Food & beverage$6,84792%
- Education$4576%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 110 | $1,639 |
| Viiv Healthcare Company | 65 | $1,045 |
| Merck | 47 | $840 |
| AbbVie(2 entities) | 37 | $729 |
| Melinta Therapeutics, LLC | 25 | $579 |
| Johnson & Johnson | 17 | $492 |
| Astellas Pharma US Inc | 16 | $436 |
| Insmed, Inc. | 11 | $320 |
| Aimmune Therapeutics, Inc. | 14 | $255 |
| La Jolla Pharmaceutical Company | 9 | $178 |
| Ferring Pharmaceuticals Inc. | 6 | $133 |
| Shionogi Inc | 6 | $122 |
| Theratechnologies Inc. | 5 | $108 |
| Tetraphase Pharmaceuticals, Inc. | 5 | $100 |
| Comsort, Inc | 1 | $100 |
| Janssen Products, LP | 1 | $99 |
| Paratek Pharmaceuticals, Inc. | 5 | $87 |
| Cumberland Pharmaceuticals, Inc. | 3 | $41 |
| Mayne Pharma Commercial LLC | 2 | $25 |
| ADMA Biomanufacturing LLC | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Pfizer | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Romark Laboratories, LC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIVEXTRO$100
How this compares
$7,404 in reported general payments places this provider in the 85th percentile of 308 infectious disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 165 | $662,919 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 93 | $390,058 |
| DovatoDolutegravir Sodium/Lamivudine | 66 | $204,394 |
| DescovyEmtricitabine/Tenofov Alafenam | 84 | $184,411 |
| JulucaDolutegravir/Rilpivirine | 35 | $126,177 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 22 | $106,042 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 23 | $91,550 |
| IsentressRaltegravir Potassium | 36 | $70,523 |
| TivicayDolutegravir Sodium | 28 | $64,047 |
| StribildElviteg/Cob/Emtri/Tenofo Disop | 13 | $62,944 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 16 | $62,351 |
| PrezcobixDarunavir/Cobicistat | 21 | $54,194 |
| Darunavir | 21 | $27,855 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 59 | $16,176 |
| Efavirenz | 20 | $9,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy, Stribild | $1,639 | $1,300,332355 claims |
| Viiv Healthcare CompanyDovato, Juluca, Triumeq, Tivicay | $1,045 | $486,168152 claims |
| Janssen Products, LPSymtuza | $99 | $106,04222 claims |
| MerckIsentress | $840 | $70,52336 claims |
| Johnson & JohnsonPrezcobix | $492 | $54,19421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 infectious disease providers in Ohio.
Other infectious disease in Canton
- Gabriel GalangCanton$6K
- Robert LeiningerCanton$5K
- Steven BurdetteDayton$322K
- Nathaniel RatnasamyFindlay$255K
- Melissa JenkinsCleveland$127K
- Grace McComseyCleveland$123K
- Steven GordonCleveland$78K
- Nicholas CongerWright Patterson Afb$76K
- Alan TaegeCleveland$76K
- Carlos MalvestuttoColumbus$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.